VYNE Therapeutics Inc. (VYNE)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, VYNE Therapeutics Inc. reported revenue of $570.0K, up 13.8% from the prior year. The company ran a net loss, with a net margin of -4646.1%. It held $30.16M in total assets against $2.40M in total liabilities.
Key ratios (FY2025)
-5219.1%
Operating margin
-4646.1%
Net margin
-95.4%
Return on equity
+13.8%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $570.0K | $501.0K | $424.0K | $477.0K | $931.0K | $20.99M | $443.0K | $3.60M | — | — |
| Cost of Revenue | — | — | — | — | $3.35M | $1.39M | $0 | $0 | — | — |
| Operating Income | -$29.75M | -$43.64M | -$29.26M | -$34.30M | -$38.91M | -$252.55M | -$95.87M | -$74.89M | -$29.59M | -$14.33M |
| Net Income | -$26.48M | -$39.83M | -$28.45M | -$23.21M | -$73.33M | -$255.57M | -$95.18M | -$74.16M | -$29.08M | -$14.07M |
| EPS (Diluted) | $-0.62 | $-0.93 | $-2.78 | $-7.28 | $-25.64 | $7.88 | — | — | — | — |
| Total Assets | $30.16M | $66.91M | $97.69M | $40.76M | $67.05M | $93.74M | $81.16M | $139.93M | $66.87M | $42.05M |
| Total Liabilities | $2.40M | $14.82M | $8.95M | $9.35M | $18.41M | $56.25M | $63.58M | $9.55M | $14.57M | $12.49M |
| Shareholders' Equity | $27.77M | $52.09M | $88.73M | $31.20M | $48.64M | $37.49M | $17.57M | $92.18M | $68.60M | -$29.44M |
| Cash & Equivalents | $24.03M | $19.93M | $30.62M | $30.91M | $42.25M | $57.56M | $43.76M | $27.87M | $10.21M | $4.03M |
| Operating Cash Flow | -$33.12M | -$33.97M | -$25.34M | -$29.20M | -$56.37M | -$137.08M | -$73.39M | -$68.66M | -$28.22M | -$2.27M |
| Capital Expenditures | $0 | $117.0K | $0 | — | — | — | — | — | — | — |
| Shares Outstanding | 33.32M | 14.83M | 14.10M | 3.23M | 2.98M | 43.21M | 9.12M | 23.23M | 5.30M | 5.28M |